The Alliance for Clinical Trials in Oncology has launched a national study aimed at improving how patients diagnosed with colorectal cancer communicate news of possible genetic risks to their ...

I was one of the first to spit into a test tube, giving up my DNA forever to learn more about my health and heredity. You know, the ones that promise to connect you with distant relatives you didn’t ...

In time for Colorectal Cancer Awareness Month in March, the Alliance for Clinical Trials in Oncology has launched a new clinical study aimed at helping improve how patients with colorectal cancer ...

A clustered family history of breast, ovarian, and colon cancers appropriately triggered germline testing, with BRCA1 mutation status informing individualized risk stratification and counseling.

Doctors say a high-risk pregnancy does not mean an unsafe delivery. With advances in genetic testing, prenatal screening, and personalised care, risks can now be detected earlier and managed ...

In 2023, Jill Martin took a test that changed her life. She underwent genetic testing for breast cancer and learned she had a BRCA2 mutation, which increases one’s risk of developing breast and other ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...

OMAHA, Neb. (WOWT) - An Omaha nurse practitioner learned she carries a gene mutation that significantly increases her cancer risk through a free research study at Nebraska Medicine. Erin Thoman, a ...

A world-first study has shown that it is possible to determine who is likely to get depression in late-life based on a "genetic score." The longitudinal study of more than 12,000 people over 70 paves ...

About a year ago, the US Food and Drug Administration (FDA) granted premarket approval to AvertD (SOLVD Health), the first genetic test to assess an individual’s risk of developing opioid use disorder ...

Eligible patients can receive up to 70 per cent in subsidies for genetic tests, while MediShield Life coverage will be extended to selected risk-reducing surgical procedures.